Immune response in COVID-19: What do we currently know?

被引:13
|
作者
Oliveira, Daniela S. [1 ]
Medeiros, Nayara I. [1 ,2 ]
Gomes, Juliana A. S. [1 ]
机构
[1] Univ Fed Minas Gerais, Lab Biol Interacoes Celulares, Dept Morfol, Inst Ciencias Biol, Belo Horizonte, MG, Brazil
[2] Fundacao Oswaldo Cruz FIOCRUZ, Imunol Celular & Mol, Inst Rene Rachou, Belo Horizonte, MG, Brazil
关键词
RESPIRATORY SYNDROME CORONAVIRUS; MERS-COV; MEMORY; SARS; REPLICATION; INFECTION; PATHOGENESIS; PATHOLOGY; CELLS; ANTIBODIES;
D O I
10.1016/j.micpath.2020.104484
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In 2002/2003 there was a pandemic denominate SARS (severe acute respiratory syndrome), caused by the SARS-CoV virus that belongs to the genera Betacoranavirus and the family Coronaviridae, generally responsible for influenza infections. In mid of 2019, a new disease by the coronavirus named by COVID-19 (SARS-CoV-2) emerged, both infections have flu symptoms, however they are infections that variable intensity, being medium to severe. In medium infections individuals have the virus and exhibit symptoms, however hospitalization is not necessary, in severe infections, individuals are hospitalized, have high pathology and in some cases progress to death. The virus is formed by simple positive RNA, enveloped, non-segmented, and presenting the largest genome of viruses constituting 32 Kb, consisting of envelope proteins, membrane, nucleocapsid and spike protein, which is essential in the interaction with the host cells. As for the origin of this virus, research has been intensified to determine this paradox and although the similarity with SARS-CoV, this virus did not has necessarily the same place of origin. As for the immune system, it is currently unknown how this new virus interacts. In this brief review, we demonstrate important considerations about the responses to this infection.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] What do we know about the adaptive immune response to covid-19?
    Stokel-Walker, Chris
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 380
  • [2] COVID-19: What do we know?
    Marshall, Steve
    Duryea, Michael
    Huang, Greg
    Kadioglu, Onur
    Mah, James
    Palomo, Juan Martin
    Rossouw, Emile
    Stappert, Dina
    Stewart, Kelton
    Tufekci, Eser
    AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS, 2020, 158 (05) : E53 - E62
  • [3] What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?
    Nancy Delgado
    Anahí Torres
    Current Oncology Reports, 2022, 24 : 645 - 650
  • [4] COVID-19 Infection and Vaccination and Its Relation to Amyloidosis: What Do We Know Currently?
    Leung, Wing-Yin
    Wu, Henry H. L.
    Floyd, Lauren
    Ponnusamy, Arvind
    Chinnadurai, Rajkumar
    VACCINES, 2023, 11 (07)
  • [5] What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?
    Delgado, Nancy
    Torres, Anahi
    CURRENT ONCOLOGY REPORTS, 2022, 24 (05) : 645 - 650
  • [6] Asthma and COVID-19: What do we know?
    Sarioglu, Nurhan
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2020, 68 (02): : 141 - 147
  • [7] COVID-19 and animals: What do we know?
    Gonultas, Serkan
    Karabagli, Murat
    Bastug, Yavuz
    Cilesiz, Nusret Can
    Kadioglu, Ates
    TURKISH JOURNAL OF UROLOGY, 2020, 46 (04): : 249 - 252
  • [8] Ivermectin in COVID-19: What do we know?
    Pandey, Sanjay
    Pathak, Subodh Kumar
    Pandey, Apurva
    Salunke, Abhijeet Ashok
    Chawla, Jasneet
    Sharma, Aryan
    Sharma, Sarthak
    Thivari, Praveen
    Ratna, Harish V. K.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (06) : 1921 - 1922
  • [9] Resuscitation in COVID-19 patients: What do we know and what should we do?
    Yilmaz, Ezgi
    Arsava, Ethem Murat
    Topcuoglu, Mehmet Akif
    CARDIOLOGY JOURNAL, 2020, 27 (05) : 656 - 657
  • [10] Pandemic preparedness beyond COVID-19: what we know, what we do, and what we do not
    Pericas, Juan M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2024, 30 (05) : 574 - 575